MARKET

CTSO

CTSO

Cytosorbents
NASDAQ

Real-time Quotes | Nasdaq Last Sale

9.55
+0.04
+0.42%
After Hours: 9.40 -0.15 -1.57% 16:13 08/07 EDT
OPEN
9.55
PREV CLOSE
9.51
HIGH
9.77
LOW
9.36
VOLUME
419.28K
TURNOVER
--
52 WEEK HIGH
11.74
52 WEEK LOW
3.490
MARKET CAP
402.85M
P/E (TTM)
-17.4908
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average CTSO stock price target is 14.50 with a high estimate of 16.00 and a low estimate of 13.00.

EPS

CTSO News

More
CTSO: 2Q20 Results Illustrate Surging Demand For CytoSorb
By M. Marin NASDAQ:CTSO READ THE FULL CTSO RESEARCH REPORT Milestone: more than 100,000 CytoSorb cartridges delivered globally Cytosorbents (NASDAQ:CTSO) reported 2Q20 revenue of $9.8 million this week, up 58% y/y and a quarterly record. Of this, $9.5 million
Zacks Small Cap Research · 2d ago
Cytosorbents Corp (CTSO) Q2 2020 Earnings Call Transcript
Joining me today are Dr. Phillip Chan, Chief Executive Officer; Vincent Capponi, Chief Operating Officer; Kathleen Bloch, Chief Financial Officer; Dr. Efthymios Deliargyris, Chief Medical Officer; Dr. Christian Steiner, Senior Vice President of Sales and Marke
Motley Fool · 3d ago
Cytosorbents EPS in-line, misses on revenue
Cytosorbents (NASDAQ:CTSO): Q2 GAAP EPS of -$0.08 in-line. Revenue of $9.8M (+57.3% Y/Y) misses by $0.15M. Shares -2.2%. Press Release
seekingalpha · 3d ago
Recap: CytoSorbents Q2 Earnings
Shares of CytoSorbents (NASDAQ:CTSO) fell 2.15% in after-market trading after the company reported Q2 results.Quarterly Results Earnings per share rose 27.27% year over year to ($0.08), which were in line with the estimate of ($0.08).Revenue of $9,795,000 rose
Benzinga · 4d ago
CytoSorbents Q2 EPS $(0.08), Inline, Sales $9.79M Beat $9.66M Estimate
CytoSorbents (NASDAQ:CTSO) reported quarterly losses of $(0.08) per share which met the analyst consensus estimate. This is a 27.27 percent increase over losses of $(0.11) per share from the same period last year. The
Benzinga · 4d ago
Earnings Outlook for CytoSorbents
CytoSorbents (NASDAQ: CTSO) releases its next round of earnings this Tuesday, August 04. Here's Benzinga's essential guide to CytoSorbents's Q2 earnings report.Earnings and Revenue CytoSorbents's EPS is expected to be at $-0.08 on sales of $9.66 million, accor
Benzinga · 5d ago
CytoSorbents Achieves Milestone of More than 100,000 CytoSorb Treatments Delivered Cumulatively To Date
CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader using its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announces that it has reached a major
PR Newswire · 5d ago
CytoSorbents Awarded $4.4 Million Contract by the U.S. Department of Defense to Complete HemoDefend-BGA Adsorber Preclinical Development
CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader specializing in blood purification, announced today that the Assistant Secretary of Defense for Health Affairs, endorsed by the Department of Defense office of the Congressionally Di
PR Newswire · 07/31 11:08

Industry

Advanced Medical Equipment & Technology
+0.47%
Healthcare Equipment & Supplies
+0.49%

Hot Stocks

Symbol
Price
%Change

About CTSO

CytoSorbents Corporation is a critical care focused immunotherapy company. The Company is engaged in commercializing its product, CytoSorb, which is a blood purification technology with focus in preventing or treating multiple organ failure. The Company's purification technologies are based on biocompatible, porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. The Company's CytoSorb is an extracorporeal cytokine filter and is designed to reduce the cytokine storm that causes inflammation, organ failure and death in common critical illnesses, such as sepsis, burn injury, trauma, lung injury and pancreatitis. In addition, CytoSorb is used in other inflammatory conditions, such as cardiac surgery, autoimmune disease flares, cancer, cytokine release syndrome in cancer immunotherapy and cancer cachexia.
More

Webull offers kinds of Cytosorbents Corp stock information, including NASDAQ:CTSO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CTSO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CTSO stock methods without spending real money on the virtual paper trading platform.